In addition, eculizumab, an anti-C5 monoclonal antibody, could be effective in controlling TMA, but it remains unclear whether this monoclonal antibody would also be effective in drug-induced thrombotic microangiopathy (DITMA) until now [27]. This evidence concerns the gene C5 and Genetic thrombotic microangiopathy.